Cancer immunotherapy in the form of immune checkpoint inhibitors and cellular therapies
has improved the treatment and prognosis of many patients. Nevertheless, most cancers are …

Sialic acid-binding immunoglobulin-like lectins (Siglecs) are a family of receptors that
recognize sialoglycans–sialic acid containing glycans that are abundantly present on cell …

Current natural killer (NK) cell-based cancer immunotherapy for the treatment of solid tumors
often exhibits insufficient cancer recognition specificity, thereby limiting therapeutic …

Immunotherapy is recognised as an attractive method for the treatment of cancer, and
numerous treatment strategies have emerged over recent years. Investigations of the tumour …

Immunosuppressive tumor microenvironments (TMEs) reduce the effectiveness of immune
responses in cancer. Mesenchymal stromal cells (MSCs), precursors to cancer-associated …

Ovarian cancer (OC) is a lethal gynecologic malignancy, with modest responses to CPI.
Engagement of additional immune arms, such as NK cells, may be of value. We focused on …

Human epidermal growth factor receptor 2 (HER2)-positive breast cancer has a high
metastatic potential. Monoclonal antibodies (mAbs) that target HER2, such as trastuzumab …

Abnormal glycosylation is a hallmark of cancer, and the hypersialylated tumor cell surface
facilitates abnormal cell trafficking and drug resistance in several malignancies, including …

Sialic acid-binding receptors are expressed on the surfaces of a variety of immune cells and
have complex and diverse immunoregulatory functions in health and diseases. Recent …

Simple Summary Hyperglycosylated cancer cells are often decorated with abundant sialic
acids, which are recognized by Sialic acid binding immunoglobulin type lectins (Siglecs) …